Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Johnson & Johnson    JNJ   US4781601046

JOHNSON & JOHNSON

 (JNJ)

91
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisionsForum 

Johnson & Johnson : J&J Chairman Weldon's Salary Cut To $1 Million After Stepping Down As CEO

05/07/2012| 05:51pm US/Eastern
Recommend:
0
   By Peter Loftus 
   Of  
 

Johnson & Johnson (JNJ) Chairman William Weldon's annual base salary was reduced by nearly half to $1 million after he stepped down as chief executive last month, the company said Monday.

Weldon's previous annual base salary was set at $1.97 million for 2012, for his roles as both chairman and CEO, but with the expectation that J&J's board would consider the appropriate compensation for Weldon in his role as chairman only.

The decrease reflects that Weldon is no longer CEO, said spokesman Al Wasilewski.

On April 26, Alex Gorsky succeeded Weldon as CEO. Weldon is continuing as chairman and will remain an employee of the company, J&J said in a quarterly report filed with the Securities and Exchange Commission Monday.

J&J said in a previous SEC filing that in his role as chairman, Weldon will work closely with Gorsky to ensure a seamless leadership transition. During this time, all day-to-day management and operational responsibilities are being transferred to Gorsky.

Weldon will remain an employee but not a member of the J&J executive committee, which is the principal management group responsible for strategic operations and allocations of the resources of the company.

Weldon's main duties as chairman will include working with the board of directors, facilitating communication between the board and management, assisting Gorsky in business planning and strategy, representing the company before governmental and other organizations, and serving as chairman of the board's finance committee.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Recommend :
0
Partner Area
React to this article
 
Latest news on JOHNSON & JOHNSON
1d ago JOHNSON & JOHNSON: J&J, in new $1 billion deal, bolsters prostate-cancer role
1d agoDJJOHNSON & JOHNSON: J&J to Acquire Privately Held Aragon Pharma
1d agoDJJOHNSON & JOHNSON: J&J to Acquire Privately Held Aragon Pharma for Up to $1 Bil..
1d ago JOHNSON & JOHNSON: to buy Aragon for up to $1 billion
1d ago JOHNSON & JOHNSON: Updated Results of Two Phase 2 ibrutinib Studies in Patients..
1d ago JOHNSON & JOHNSON: Announces Definitive Agreement To Acquire Aragon Pharmaceuti..
4d agoDJJOHNSON & JOHNSON: FDA Approves Mentor's Silicone Breast Implant
5d agoDJLilly Ends Alzheimer's Drug Study On Safety Concern
6d agoDJGlaxo Probes China Bribe Claims
6d ago JOHNSON & JOHNSON: Cordis Announces FDA Clearance of the ADROIT? Guiding Cathet..
Advertisement
Chart
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Income Statement Evolution
Johnson _ Johnson : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF
Copyright © 2013 Surperformance. All rights reserved.